ADYX Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EDT
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.02 - $0.02
Previous CloseN/A
Volume1.00
Average Volume (3M)N/A
Market Cap
$6.00
Enterprise Value-$8.87M
Total Cash (Recent Filing)$331.00K
Total Debt (Recent Filing)$9.48M
Price to Earnings (P/E)―
Beta-195.90
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.79
Shares Outstanding5,808,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.12
Price to Sales (P/S)4.15
P/FCF Ratio-0.95
Enterprise Value/Market Cap-1.48M
Enterprise Value/Revenue-15.06
Enterprise Value/Gross Profit-2.96K
Enterprise Value/Ebitda1.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ADYX FAQ
What was Adynxx, Inc.’s price range in the past 12 months?
Adynxx, Inc. lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is Adynxx, Inc.’s market cap?
Adynxx, Inc.’s market cap is $6.00.
When is Adynxx, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Adynxx, Inc.’s earnings last quarter?
Adynxx, Inc. released its earnings results on Aug 14, 2019. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.87.
Is Adynxx, Inc. overvalued?
According to Wall Street analysts Adynxx, Inc.’s price is currently Overvalued.
Does Adynxx, Inc. pay dividends?
Adynxx, Inc. pays a Monthly dividend of $6.3 which represents an annual dividend yield of N/A. See more information on Adynxx, Inc. dividends here
What is Adynxx, Inc.’s EPS estimate?
Adynxx, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adynxx, Inc. have?
Adynxx, Inc. has 5,808,000 shares outstanding.
What happened to Adynxx, Inc.’s price movement after its last earnings report?
Adynxx, Inc. reported an EPS of -$0.87 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Adynxx, Inc.?
Currently, no hedge funds are holding shares in ADYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Adynxx, Inc.
Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort. Additionally, AYX2 is a pre-clinical candidate being explored for its potential in treating localized chronic pain. Established in 2007, the company's corporate headquarters are situated in San Francisco, California.